Michelangelo Fiorentino

Pattern‐based interpretation of SOX2 expression in ovarian teratomas: avoiding diagnostic pitfalls in the distinction between immature and mature neuroectodermal elements

Agnese Orsatti, Caterina Ravaioli, Marco Grillini, Eugenia Franchini et autres

AIMS: The distinction between ovarian immature teratoma (IT) and mature teratoma (MT) relies on the identification of immature neuroectodermal tissue in the former, a task that may be challenging in some tumours and carries significant prognostic and therapeutic implications. SRY-box transcription factor …

it, pt, us, gb (code pays fourni par la source)

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis

Alessandra Morselli, Chiara Miroglio, William Kothalawala, Idan Lahat et autres

Abstract Patients with non-small cell lung cancer (NSCLC) carrying activating EGFR mutations typically respond favorably to third-generation EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. Nevertheless, resistance almost inevitably emerges, ultimately limiting the durability of these treatments. We investigated non-genomic mechanisms enabling …

it, hu, il (code pays fourni par la source)

Eine große erythematöse Plaque der Kopfhaut

Tullio Brunetti, Costantino Ricci, Federico Bardazzi, Michelangelo Fiorentino et autres

it (code pays fourni par la source)

FGFR1 mutations identified in FOXL2-wild type ovarian adult granulosa cell tumors are not present in testicular counterparts: Re-analysis of a multi-institutional series

Costantino Ricci, Dario de Biase, Thais Maloberti, Agnese Orsatti et autres

Testicular adult granulosa cell tumors (AGCTs) are rare and show several clinical, pathological, and molecular differences with their ovarian counterparts. FOXL2 p.Cys134Trp, the ubiquitous molecular driver of ovarian AGCTs, is infrequent (~ 7%) in testicular AGCTs. Recently, FGFR1 hotspot mutations were reported …

it, us, pt, cz, nl, au (code pays fourni par la source)

Abstract 4475: Neuroendocrine-like dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis.

Alessandra Morselli, Chiara Miroglio, William Jayasekara Kothalawala, Donatella Romaniello et autres

Abstract Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations, such as exon 19 deletions (del746-750) and the L858R point mutation in exon 21, respond well to third-generation tyrosine kinase inhibitors (TKIs) like osimertinib. However, resistance inevitably emerges, limiting the long-term …

it, hu, il (code pays fourni par la source)

Percutaneous Radiofrequency Ablation for Bosniak III-IV Cysts: A 5-Year Institutional Experience

Attilio Barretta, Pietro Piazza, Andrea Boccatonda, Alice Brighenti et autres

Background and Aim: Percutaneous radiofrequency ablation (RFA) is an increasingly adopted treatment for small solid renal masses. However, its safety and oncological effectiveness in complex renal cysts, classified as Bosniak III and IV, remain poorly characterized. We aimed to evaluate oncological outcomes …

it (code pays fourni par la source)

1595 IMPACTS Study: Independent-validation of Modified Pulmonary Adenocarcinoma Classification on T Stage

Francesca Ambrosi, Margherita Mottola, Moira Ragazzi, A. Cavazza et autres

it, ch, us, nl, au, gb, de (code pays fourni par la source)

846 Eosinophilic Vacuolated Tumor with Worrisome Morphologic Features May Have Metastatic Potential

Ngoc-Nhu Jennifer Nguyen, Michelle S. Hirsch, Liang Cheng, Maria Tretiakova et autres

ca, us, de, tr, it (code pays fourni par la source)

1594 Extrapleural Mesotheliomas: Clinicopathologic and Immunohistochemical Features Applying the WHO 2021 Pleural Mesothelioma Grading System

Francesca Ambrosi, Agnese Orsatti, Federico Chiarucci, Giulia Raffaella Galli et autres

it (code pays fourni par la source)

Supplementary File 1 from Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer

Sinéad Flanagan, Rosina T. Lis, Ying Huang, Lina E. Jehane et autres

Supplementary File 1

Data from Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer

Sinéad Flanagan, Rosina T. Lis, Ying Huang, Lina E. Jehane et autres

Abstract Prostate tumor cells produce cholesterol de novo, and statin therapy targets the initial rate-limiting enzyme in this process, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR). The extent to which the expression of HMGCR in prostate tumors could influence progression and predict the potential antineoplastic …

Supplementary Table S1 from Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer

Sinéad Flanagan, Rosina T. Lis, Ying Huang, Lina E. Jehane et autres

Table S1. shRNA design.